Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall
Histopathology · 2024-02 · 84 (3) · 507-514
DOI: 10.1111/his.15094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 15.11.2023. Verfasst von João Lobo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Adenocarcinoma, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Aims
The distinction of high‐grade prostate cancer (PCa) from poorly differentiated urothelial carcinoma (UC) can be somewhat challenging on clinical and morphological grounds alone, yet it is of great importance for prognostication and choice of treatment. GATA3 is a useful immunohistochemical marker to confirm urothelial origin. However, recent works report strong GATA3 immunoexpression in primary high‐grade PCa. The aim of this study was to explore GATA3 expression specifically in metastatic PCa. Methods and results The pathology databases of four tertiary institutions were queried for cases of metastatic PCa. Available slides and clinical records were reviewed by experienced genitourinary pathologists. Prostatic markers (PSA, PSAP, NKX3.1) and GATA3 immunohistochemistry were performed. A total of 163 metastatic PCa cases were included. At least one prostate marker was positive in each case of non‐regional distant metastasis, confirming prostatic origin. GATA3 strong staining was found in four (2.5%) cases: two liver, one bone and one non‐regional lymph‐node metastases. All four patients had Grade Group 5 PCa at the initial diagnosis. The metastatic prostatic adenocarcinomas were solid, either with no gland formation ( n = 3) or with only focal cribriforming ( n = 1).
Conclusions
To our knowledge, this is the first study exploring GATA3 expression specifically in metastatic PCa. Despite being infrequent, GATA3 positivity in high‐grade PCa may lead to misdiagnosis, with clinical implications. We recommend a panel of immunohistochemical markers, both prostatic and urothelial, for ruling out UC, either in primary tumour samples or in the event of metastases of unknown primary, when a genitourinary origin is suspected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal.
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC) & RISE@CI-IPOP (Health Research…
- Department of Pathology and Molecular Immunology, ICBAS - School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal.
- Department of Pathology, Università Vita-Salute San Raffaele, Milano, Italy.
- Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: João Lobo, Nazario P Tenace, Cristina Magi-Galluzzi
Zitieren
APA
Lobo, J., Tenace, N. P., Cañete-Portillo, S., Carneiro, I., Henrique, R., Lucianò, R., Harik, L. R., & Magi-Galluzzi, C. (2024). Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall. Histopathology, 84(3), 507-514. https://doi.org/10.1111/his.15094
Vancouver
Lobo J, Tenace NP, Cañete-Portillo S, Carneiro I, Henrique R, Lucianò R, et al. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall. Histopathology. 2024;84(3):507-514. doi:10.1111/his.15094
BibTeX
@article{Lobo2024,
author = {Lobo, João and Tenace, Nazario P and Cañete-Portillo, Sofia and Carneiro, Isa and Henrique, Rui and Lucianò, Roberta and Harik, Lara R and Magi-Galluzzi, Cristina},
title = {Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall},
journal = {Histopathology},
year = {2024},
volume = {84},
number = {3},
pages = {507--514},
doi = {10.1111/his.15094}
}
EUVIMED